Seeing gut inflammation with a glowing dye during a scope
Treatments studied
Part of Digestive system clinical trials.
This study tests a new way to see inflammation in the gut during a colonoscopy by using special dye attached to two IBD medications (adalimumab and risankizumab). The dye makes the medication glow under a special camera, which may help doctors see exactly where and how much inflammation is present, potentially guiding better treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn's disease or ulcerative colitis.
- Your disease is active, meaning you have symptoms or test results (like a stool test) showing inflammation.
- Your doctor has decided you can receive one of the study drugs: adalimumab or risankizumab.
- You are scheduled to have a colonoscopy or similar procedure.
- You are at least 18 years old and can give written consent.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
This study uses a special camera capsule to map the gut's natural bacteria in people with ulcerative colitis or Crohn's disease, compared to healthy volunteers. The goal is to better understand how these bacteria affect the disease, which could lead to better treatments.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.